| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Benjamin A. Lipsky | Q37830281 |
| İlker Uçkay | Q87399310 | ||
| P2093 | author name string | Mohamed Abbas | |
| P2860 | cites work | Concordance in diabetic foot ulcer infection | Q30532685 |
| Antibiotic utilization: is there an effect on antimicrobial resistance? | Q31920790 | ||
| Antibiotic side effects | Q31974254 | ||
| Application of gentamicin-collagen sponge shortened wound healing time after minor amputations in diabetic patients - a prospective, randomised trial | Q33701282 | ||
| Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up | Q33859977 | ||
| Evidence-based antibiotic therapy of diabetic foot infections | Q33881703 | ||
| Choice of wound care in diabetic foot ulcer: A practical approach | Q34023583 | ||
| Surgical treatment of the diabetic foot | Q34072015 | ||
| Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate | Q34284305 | ||
| Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. | Q34468030 | ||
| Larval therapy: a novel treatment in eliminating methicillin-resistant Staphylococcus aureus from diabetic foot ulcers | Q34607117 | ||
| Mini-review: Lactoferrin: a bioinspired, anti-biofilm therapeutic | Q34650340 | ||
| Topical antimicrobial therapy for treating chronic wounds | Q35008676 | ||
| Oral antibiotic treatment induces skin microbiota dysbiosis and influences wound healing | Q35318834 | ||
| Defined and refined: criteria for identifying wound infection revisited | Q35695416 | ||
| Controversies in diagnosing and managing osteomyelitis of the foot in diabetes | Q35861300 | ||
| Remission after treatment of osteoarticular infections due to Pseudomonas aeruginosa versus Staphylococcus aureus: a case-controlled study | Q35913969 | ||
| Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents | Q36098587 | ||
| Systematic review of antimicrobial treatments for diabetic foot ulcers | Q36451493 | ||
| Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study | Q36592698 | ||
| Oral antimicrobial therapy for diabetic foot osteomyelitis | Q36630236 | ||
| Effectiveness of interventions in reducing antibiotic use for upper respiratory infections in ambulatory care practices | Q36677161 | ||
| Moxifloxacin in complicated skin and skin structure infections (cSSSIs): A prospective, international, non-interventional, observational study | Q36997690 | ||
| Treatment of diabetic foot ulcer: an overview strategies for clinical approach | Q37065721 | ||
| Antimicrobial drug use and resistance in Europe | Q37072235 | ||
| Ulcer healing time and antibiotic treatment before and after the introduction of the Registry of Ulcer Treatment: an improvement project in a national quality registry in Sweden | Q37121705 | ||
| Foreign body infections due to Staphylococcus epidermidis | Q37249440 | ||
| Antibiotic consumption and link to resistance | Q37444150 | ||
| Toenail onychomycosis in diabetic patients: issues and management | Q37505018 | ||
| Expert opinion on the management of infections in the diabetic foot | Q37978287 | ||
| A review of the scientific evidence for biofilms in wounds | Q38044030 | ||
| Prevention of surgical site infections in orthopaedic surgery and bone trauma: state-of-the-art update | Q38082013 | ||
| Diabetic foot infections: state-of-the-art | Q38126226 | ||
| Do diabetic foot infections with methicillin-resistant Staphylococcus aureus differ from those with other pathogens? | Q38257503 | ||
| Phenotypic and genotypic characterisation of Staphylococcus aureus causing musculoskeletal infections. | Q39203145 | ||
| Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial | Q39467852 | ||
| Current aspects in the pathophysiology and treatment of chronic wounds in diabetes mellitus | Q40193187 | ||
| Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study | Q41653869 | ||
| Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis | Q42232433 | ||
| Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital | Q43260800 | ||
| Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections | Q43273792 | ||
| Predicting the pathogen of diabetic toe osteomyelitis by two consecutive ulcer cultures with bone contact | Q43507618 | ||
| Topical application of a gentamicin-collagen sponge combined with systemic antibiotic therapy for the treatment of diabetic foot infections of moderate severity: a randomized, controlled, multicenter clinical trial | Q43520816 | ||
| Wound healing potential of topical bacteriophage therapy on diabetic cutaneous wounds | Q43700519 | ||
| Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis | Q43815771 | ||
| The diabetic foot infections: biofilms and antimicrobial resistance | Q43969138 | ||
| Primarily non-surgical management of osteomyelitis of the foot in diabetes | Q44201456 | ||
| An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers | Q44294929 | ||
| Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients | Q44384585 | ||
| Effect of daptomycin on local interleukin-6, matrix metalloproteinase-9, and metallopeptidase inhibitor 1 in patients with MRSA-infected diabetic foot | Q44561865 | ||
| Images in clinical medicine. Evolution of a diabetic foot infection | Q45047303 | ||
| Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in old | Q45161084 | ||
| Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections | Q45230598 | ||
| Antibiotic misuse: a global crisis | Q45710473 | ||
| Conservative management of diabetic foot osteomyelitis. | Q45981909 | ||
| Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream | Q46260034 | ||
| Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial | Q46533293 | ||
| Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study | Q46815624 | ||
| Biofilms in chronic wounds | Q48021357 | ||
| 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections | Q48676820 | ||
| Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled study--the D.A.N.T.E (Diabetic ulcer Antimicrobial New Topical treatment Evaluation) study. | Q50482092 | ||
| Point prevalence of wounds and cost impact in the acute and community setting in Denmark. | Q50559480 | ||
| Should the methicillin-resistant Staphylococcus aureus carriage status be used as a guide to treatment for skin and soft tissue infections? | Q50966241 | ||
| Bone of contention: diagnosing diabetic foot osteomyelitis. | Q53405159 | ||
| Addressing antibiotic use for acute respiratory tract infections in an academic family medicine practice. | Q54549064 | ||
| Treating Diabetic Foot Osteomyelitis Primarily With Surgery or Antibiotics: Have We Answered the Question? | Q57543591 | ||
| Empirical therapy for diabetic foot infections: are there clinical clues to guide antibiotic selection? | Q57543717 | ||
| Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin–tazobactam/amoxicillin–clavulanate | Q57543731 | ||
| Risk Factors for Foot Infections in Individuals With Diabetes | Q57543754 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibiotic | Q12187 |
| P304 | page(s) | 821-832 | |
| P577 | publication date | 2015-03-03 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | In diabetic foot infections antibiotics are to treat infection, not to heal wounds | |
| P478 | volume | 16 |
| Q33629050 | A Proposed New Classification of Skin and Soft Tissue Infections Modeled on the Subset of Diabetic Foot Infection |
| Q55413038 | A randomized controlled trial of the safety and efficacy of a topical gentamicin-collagen sponge in diabetic patients with a mild foot ulcer infection. |
| Q58803225 | A randomized, controlled study to investigate the efficacy and safety of a topical gentamicin-collagen sponge in combination with systemic antibiotic therapy in diabetic patients with a moderate or severe foot ulcer infection |
| Q35805594 | Analysis of the chronic wound microbiota of 2,963 patients by 16S rDNA pyrosequencing |
| Q99709279 | Antibacterial-Integrated Collagen Wound Dressing for Diabetes-Related Foot Ulcers: An Evidence-Based Review of Clinical Studies |
| Q38919687 | Antimicrobial stewardship in wound care: a Position Paper from the British Society for Antimicrobial Chemotherapy and European Wound Management Association |
| Q38673550 | Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns. |
| Q57299847 | Current concepts for the evaluation and management of diabetic foot ulcers |
| Q40053813 | Diabetic foot infection: Antibiotic therapy and good practice recommendations. |
| Q26783946 | Diabetic foot infections: what have we learned in the last 30 years? |
| Q90354781 | Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update) |
| Q43194060 | Is surgical debridement necessary in the diabetic foot treated with photodynamic therapy? |
| Q53696531 | Microbiology and Antimicrobial Therapy for Diabetic Foot Infections. |
| Q40524232 | Microbiota is a primary cause of pathogenesis of chronic wounds |
| Q64098471 | New Approach in Ulcer Prevention and Wound Healing Treatment using Doxycycline and Amoxicillin/LDH Nanocomposites |
| Q39060534 | New horizons in the understanding of the causes and management of diabetic foot disease: report from the 2017 Diabetes UK Annual Professional Conference Symposium |
| Q40602960 | Optimising the quality and outcomes of treatments for diabetic foot infections |
| Q90380763 | Prevalence and interrelationships of foot ulcer, risk-factors and antibiotic resistance in foot ulcers in diabetic populations: A systematic review and meta-analysis |
| Q64228186 | Stopping antibiotics after surgical amputation in diabetic foot and ankle infections-A daily practice cohort |
| Q48043438 | Update on management of diabetic foot ulcers. |
Search more.